Shire to Buy Baxalta for $32 Billion
January 11, 2016.
Shire announced today that it has entered into an agreement to acquire Baxalta under a cash and stock deal valued at $45.57 per share, or approximately $32 billion.
The combination of Baxalta and Shire would reportedly create "the number-one rare diseases platform in revenue and pipeline depth", with best-in-class products in each of the following franchises: hematology, immunology, neuroscience, lysosomal storage diseases, gastrointestinal/endocrine, and hereditary angioedema (HAE).
Shire CEO Flemming Ornskov said that the expanded portfolio "will drive our growth to over $20 billion in anticipated annual revenues by 2020."
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
